The University of New South Wales

A UNSW study suggests adding TETA (Cuprior) to neuroblastoma treatment improves health by shrinking tumors and boosting immunity, potentially increasing survival rates from 10 to 50%. The drug transfers copper to immune cells, weakening tumors and enhancing immunotherapy response. It's non-toxic, cost-effective, and could improve quality of life for affected children.

A study by UNSW suggests adding TETA (Cuprior) to treat neuroblastoma improves tumor shrinkage and immune response, potentially raising survival rates from 10 to 50%. The drug transfers copper to immune cells, weakening tumors and enhancing immunotherapy, with no toxic side effects.